Drug Trial Radar · NCT01211847
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Jan 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Oct 2010
Primary completion
Sep 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Essentialis, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Sep 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Once a day oral administration with DCCR helps lower triglycerides
Conditions
- Hypertriglyceridemia
- Dyslipidemia
Interventions
Diazoxide Choline Controlled-Release TabletDrug
DCCR 290 mg once a day for 126 days
PlaceboDrug
Placebo matching DCCR
Primary outcomes
What the sponsor says the trial is designed to measure.
- Triglyceride-lowering efficacy of DCCRTime frame: 84 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.